|Back to main|
Biotech Emmaus Holdings withdraws $29 million IPO
7/26/2013 10:48:00 AM
By: Renaissance Capital
Emmaus Holdings, or more commonly Emmaus Life Sciences, a biotech focused on the treatment of sickle cell disease and other rare diseases, withdrew its plans for an initial public offering on Friday. The company remains embroiled in a lawsuit with AFH Holdings since 2012, an advisory firm that was suppose to assist Emmaus in becoming a public company. The Torrance, CA-based company was founded in 2007 and last updated its filing in April 2012. Aegis Capital was set to be the sole bookrunner on the deal.